Tag Archives: ARV-110

17Dec/20

New PROTAC Interim Data Released—Potential ARV-471 Won Arvinas Doubled Shares

December 17, 2020PROTAC News, PROTAC ResearchARV-110, ARV-471, estrogen receptor, protacbiolabs

On December 14, 2020, Arvinas released the latest clinical data of ARV-471 and ARV-110, which showed strong therapeutic potential. As soon as the news was released, Arvinas’s share price doubled, with aRead More…

29May/20

The First PROTAC Drug ARV-110’s Latest Clinical Data: Preliminary Display of Anti-tumor Activity

May 29, 2020PROTAC News, PROTAC Researchandrogen receptor, AR, ARV-110, protacbiolabs

Among the drugs developed in Arvinas, ARV-110 is the first oral PRAOTC small molecule drug to enter clinical trials in the field of proteolytic targeted chimerism, selectively targeting the degradation of androgenRead More…

PROTAC Research
PROTAC News